The U.S. Food and Drug Administration issued an emergency use authorization on Wednesday for Pfizer’s antiviral pill for the treatment of mild-to-moderate COVID-19 infection.
“Today’s authorization introduces the first treatment for COVID-19 that is in the form of a pill that is taken orally — a major step forward in the fight against this global pandemic. This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19,” said Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research.
Pfizer’s Paxlovid becomes the first US authorized home COVID-19 treatment. The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited, Newsmax reported.
FDA Press Release:
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
Paxlovid is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. Paxlovid is not a substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended. The FDA has approved one vaccine and authorized others to prevent COVID-19 and serious clinical outcomes associated with a COVID-19 infection, including hospitalization and death. The FDA urges the public to get vaccinated and receive a booster if eligible. Learn more about FDA-approved or -authorized COVID-19 vaccines.
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations. Paxlovid is administered as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. Paxlovid is not authorized for use for longer than five consecutive days.
Read more here.
An antiviral pill from Merck & Co. also is expected soon to be authorized for COVID-19 treatment. The Gateway Pundit previously reported that a new international report of 64 studies shows Ivermectin has an 86% success rate as prophylaxis and a 67% success rate in the early treatment of coronavirus.
Two Oklahoma doctors, Dr. John Sutton and Dr. David Jayne also shared their success stories about the use of Ivermectin as a treatment for their patients with COVID-19.
Highly popular podcast host Joe Rogan said he recovered in 3 days after taking monoclonal antibodies, Ivermectin, Z-pak, prednisone, IV vitamin drip.
Even our contributor Wayne Root, beat the COVID-19 in 48 hours with Ivermectin, just like Joe Rogan.
Uttar Pradesh in India and Indonesia started to see COVID-19 cases fall precipitously after its government granted the Emergency Use Authorization for Ivermectin as the therapeutic drug to cure the Covid-19. You can read more of this story here and here.
The post JUST IN: FDA Authorizes Pfizer Antiviral Pill for COVID-19 Home Treatment appeared first on The Gateway Pundit.